The FDA approved denileukin diftitox (Lymphir), the first novel targeted systemic therapy approved for relapsed/refractory (r/r) cutaneous T-cell lymphoma (CTCL) since 2018, Citius Pharmaceuticals ...
Findings spotlighted in oral presentation at the 5 th annual World Congress of Cutaneous Lymphomas meeting in Pasadena, CA CTCL is a rare form of non-Hodgkin lymphoma that most prominently affects the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback